Â鶹ԭ´´

The global Soliris market size was valued at US$ million in 2023. With growing demand in downstream market, the Soliris is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Soliris market. Soliris are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Soliris. Â鶹ԭ´´ players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Soliris market.
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Prior to COVID-19, the China market for Soliris was anticipated to grow from US$ 43.15 million in 2020 to US$ 105.67 million by 2026; it is expected to grow at a CAGR of 14.86% during 2021–2026, whereas post-COVID-19 scenario, the market for Soliris is projected to grow from US$ 40.9 million in 2020 (a change by ~-6.4% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ 100.58 million by 2026; it is expected to grow at a CAGR of 14.75% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Soliris market.The classification of Soliris includes Plasma Exchange and Plasma Infusion, and the proportion of Plasma Exchange in 2019 is about 76.36%, and the proportion is in increasing trend from 2013 to 2018.

Soliris is widely used for patients of PNH, aHUS and other. The most proportion of Soliris is used for patients of PNH, and the proportion in 2019 is 66.85%.
Key Features:
The report on Soliris market reflects various aspects and provide valuable insights into the industry.
Â鶹ԭ´´ Size and Growth: The research report provide an overview of the current size and growth of the Soliris market. It may include historical data, market segmentation by Type (e.g., Plasma Exchange, Plasma Infusion), and regional breakdowns.
Â鶹ԭ´´ Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Soliris market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Soliris market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Soliris industry. This include advancements in Soliris technology, Soliris new entrants, Soliris new investment, and other innovations that are shaping the future of Soliris.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Soliris market. It includes factors influencing customer ' purchasing decisions, preferences for Soliris product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Soliris market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Soliris market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Soliris market.
Â鶹ԭ´´ Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Soliris industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Soliris market.
Â鶹ԭ´´ Segmentation:
Soliris market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Plasma Exchange
Plasma Infusion
Segmentation by application
PNH
aHUS
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alexion
Key Questions Addressed in this Report
What is the 10-year outlook for the global Soliris market?
What factors are driving Soliris market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Soliris market opportunities vary by end market size?
How does Soliris break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.